{"id":"cyclophosphamide-fludarabine-anti-thymocyte-globulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression / neutropenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Graft-versus-host disease (GVHD)"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":{"chemblId":"CHEMBL2109145","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is an alkylating agent that causes DNA cross-linking and cell death across multiple cell types. Fludarabine is a purine analog that inhibits DNA synthesis and induces apoptosis in lymphocytes. Anti-thymocyte globulin (ATG) is a polyclonal antibody preparation that depletes T cells through complement-dependent and antibody-dependent cellular cytotoxicity. Together, this combination provides intensive immunosuppression and myeloablation suitable for conditioning prior to allogeneic hematopoietic stem cell transplantation.","oneSentence":"This combination regimen uses cyclophosphamide and fludarabine to deplete immune cells, followed by anti-thymocyte globulin to further suppress T-cell mediated rejection, typically used as conditioning for hematopoietic stem cell transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:15.396Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies"},{"name":"Conditioning regimen for allogeneic hematopoietic stem cell transplantation in severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT06517641","phase":"PHASE2","title":"Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-05-12","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT04083183","phase":"PHASE1, PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":"Non-Malignant Neoplasm","enrollment":40},{"nctId":"NCT03622788","phase":"PHASE1, PHASE2","title":"Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia","enrollment":16},{"nctId":"NCT02990819","phase":"PHASE2","title":"Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2016-12","conditions":"Immunodeficiencies, Immune Dysregulation Syndromes","enrollment":60},{"nctId":"NCT02727803","phase":"PHASE2","title":"Personalized NK Cell Therapy in CBT","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-19","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia","enrollment":100},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT04872595","phase":"PHASE2","title":"A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-30","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Myelodysplastic Syndromes (MDS)","enrollment":59},{"nctId":"NCT03531736","phase":"PHASE1","title":"T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-09","conditions":"Myeloid Diseases","enrollment":17},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT04558736","phase":"PHASE2","title":"Haploidentical HCT for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-01-21","conditions":"Aplastic Anemia, Bone Marrow Failure Syndrome","enrollment":21},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT02845596","phase":"NA","title":"Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Michael Pulsipher","startDate":"2016-08","conditions":"Severe Aplastic Anemia","enrollment":40},{"nctId":"NCT02162420","phase":"NA","title":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-01-10","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":61},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT03615105","phase":"PHASE2","title":"Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-25","conditions":"Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)","enrollment":9},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT02179359","phase":"NA","title":"Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2014-09-02","conditions":"Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia","enrollment":38},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT06512545","phase":"NA","title":"Modified Second Haplo-transplantation for Graft Failure","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07-01","conditions":"Graft Failure, Stem Cell Transplant Complications","enrollment":12},{"nctId":"NCT01019876","phase":"PHASE2, PHASE3","title":"Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-09","conditions":"Bone Marrow Failure, Osteopetrosis, Fanconi Anemia","enrollment":38},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT02582775","phase":"PHASE2","title":"MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Epidermolysis Bullosa","enrollment":17},{"nctId":"NCT03367546","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-07-02","conditions":"Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders","enrollment":5},{"nctId":"NCT05832515","phase":"PHASE1","title":"AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-10-01","conditions":"Multiple Sclerosis","enrollment":200},{"nctId":"NCT01751997","phase":"PHASE2, PHASE3","title":"Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors","status":"COMPLETED","sponsor":"Byung-Sik Cho","startDate":"2013-01","conditions":"Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT01033552","phase":"PHASE1, PHASE2","title":"Biochemical Correction of Severe EB by Allo HSCT and \"Off-the-shelf\" MSCs","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2010-01","conditions":"Epidermolysis Bullosa","enrollment":32},{"nctId":"NCT03412409","phase":"PHASE2","title":"RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Acute Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT00003552","phase":"PHASE1, PHASE2","title":"Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-01","conditions":"Stage IV Melanoma, Recurrent Melanoma","enrollment":""},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT06098326","phase":"PHASE2","title":"CyFluATG in Lower Risk MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asan Medical Center","startDate":"2018-03-06","conditions":"Myelodysplastic Syndromes","enrollment":30},{"nctId":"NCT02757885","phase":"PHASE2","title":"Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-07-10","conditions":"Sickle Cell Disease","enrollment":10},{"nctId":"NCT03096782","phase":"PHASE2","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia","enrollment":6},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT01044745","phase":"PHASE2","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-12-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT02918292","phase":"PHASE2","title":"Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-07-03","conditions":"Severe Aplastic Anemia","enrollment":32},{"nctId":"NCT02833805","phase":"PHASE2","title":"NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09","conditions":"Severe Aplastic Anemia, Aplastic Anemia, Bone Marrow Failure","enrollment":21},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT03412266","phase":"PHASE2","title":"RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-02-01","conditions":"Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT03600909","phase":"PHASE2","title":"A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-05-15","conditions":"Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)","enrollment":3},{"nctId":"NCT00258427","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-03-26","conditions":"Fanconi Anemia","enrollment":14},{"nctId":"NCT00630253","phase":"PHASE1, PHASE2","title":"Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-02-17","conditions":"Fanconi Anemia","enrollment":31},{"nctId":"NCT00003816","phase":"PHASE2, PHASE3","title":"Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1998-10-19","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":361},{"nctId":"NCT03602898","phase":"PHASE2","title":"Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-06-01","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia","enrollment":""},{"nctId":"NCT00886522","phase":"PHASE2","title":"Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2009-04","conditions":"Hematological Malignancies","enrollment":23},{"nctId":"NCT02876679","phase":"PHASE2","title":"Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-04-06","conditions":"Graft vs Host Disease","enrollment":94},{"nctId":"NCT00305682","phase":"PHASE2","title":"Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-06","conditions":"Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":295},{"nctId":"NCT03593902","phase":"PHASE2, PHASE3","title":"Cardiac Safe Transplants for Systemic Sclerosis","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2018-05-17","conditions":"Systemic Sclerosis, Scleroderma","enrollment":9},{"nctId":"NCT03955601","phase":"PHASE2","title":"A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:","status":"UNKNOWN","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2018-07-12","conditions":"Aplastic Anemia Idiopathic","enrollment":30},{"nctId":"NCT00068523","phase":"NA","title":"Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2003-06","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":10},{"nctId":"NCT00054236","phase":"PHASE1","title":"Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2002-05","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":55},{"nctId":"NCT01445821","phase":"PHASE3","title":"Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2011-09-15","conditions":"Scleroderma, Systemic","enrollment":44},{"nctId":"NCT01370213","phase":"PHASE2","title":"NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-09","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT00303719","phase":"PHASE2","title":"Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-03-26","conditions":"Kidney Cancer, Leukemia, Lymphoma","enrollment":342},{"nctId":"NCT00566696","phase":"PHASE2","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-14","conditions":"Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML)","enrollment":73},{"nctId":"NCT00923364","phase":"PHASE2","title":"Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-05-07","conditions":"MDS, Immunodeficiency, GATA2","enrollment":19},{"nctId":"NCT00498316","phase":"PHASE1","title":"Cord Blood Expansion on Mesenchymal Stem Cells","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-07-03","conditions":"Myelodysplastic Syndrome, Leukemia","enrollment":98},{"nctId":"NCT00176852","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Hemoglobinopathy","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-06","conditions":"Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia","enrollment":22},{"nctId":"NCT00053989","phase":"PHASE2","title":"NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2002-01-29","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":41},{"nctId":"NCT02080195","phase":"PHASE1, PHASE2","title":"Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-09-13","conditions":"Lupus Erythematosus, Graft-versus-host Disease","enrollment":1},{"nctId":"NCT00489281","phase":"PHASE2","title":"Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-06-23","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT00801931","phase":"PHASE1, PHASE2","title":"Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders","status":"TERMINATED","sponsor":"Columbia University","startDate":"2007-09-06","conditions":"Leukemia, Lymphoma, Neuroblastoma","enrollment":1},{"nctId":"NCT03295058","phase":"PHASE2, PHASE3","title":"Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-01-01","conditions":"Severe Aplastic Anemia","enrollment":50},{"nctId":"NCT02029638","phase":"PHASE2","title":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-07","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT01049854","phase":"PHASE2","title":"CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2011-09","conditions":"Leukemia, Lymphoma, Bone Marrow Failure","enrollment":20},{"nctId":"NCT02428517","phase":"","title":"Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2015-04","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":20},{"nctId":"NCT01037764","phase":"PHASE2","title":"Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Asan Medical Center","startDate":"2010-01","conditions":"Acute Lymphoid Leukemia","enrollment":100},{"nctId":"NCT02702960","phase":"PHASE2","title":"Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03","conditions":"Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT00113828","phase":"PHASE2","title":"Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2004-12","conditions":"Lymphoma, Leukemia, Multiple Myeloma","enrollment":5},{"nctId":"NCT00455312","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-08","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":36},{"nctId":"NCT00365287","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-06","conditions":"Breast Cancer, Kidney Cancer, Leukemia","enrollment":148},{"nctId":"NCT00425802","phase":"PHASE2","title":"Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-11-28","conditions":"Leukemia, Lymphoma","enrollment":61},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT01362452","phase":"PHASE1","title":"Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-12-07","conditions":"Leukemia, Lymphoma","enrollment":5},{"nctId":"NCT00968162","phase":"PHASE1","title":"Sickle Cell Disease Conditioning for Bone Marrow Transplant","status":"COMPLETED","sponsor":"Emory University","startDate":"2009-02","conditions":"Bone Marrow Transplantation, Sickle Cell Disease","enrollment":8},{"nctId":"NCT00281983","phase":"PHASE1, PHASE2","title":"Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2000-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":100},{"nctId":"NCT00691015","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2008-05","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":48},{"nctId":"NCT00719849","phase":"PHASE2","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-11","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":13},{"nctId":"NCT02259348","phase":"PHASE2","title":"Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-10","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":12},{"nctId":"NCT00914849","phase":"PHASE2","title":"Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-08","conditions":"Hematologic Neoplasms","enrollment":68},{"nctId":"NCT02472392","phase":"PHASE1","title":"Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-04","conditions":"EWINGS SARCOMA","enrollment":10},{"nctId":"NCT02014506","phase":"PHASE1, PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2017-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation, Malignant Disease, Non-malignant Disease","enrollment":30},{"nctId":"NCT01621477","phase":"PHASE2","title":"T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia","enrollment":34},{"nctId":"NCT01020734","phase":"PHASE2","title":"Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2011-05","conditions":"Leukemia","enrollment":263},{"nctId":"NCT00028730","phase":"PHASE2","title":"Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-08","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":25},{"nctId":"NCT01067300","phase":"PHASE3","title":"A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2010-02","conditions":"Leukemia","enrollment":198},{"nctId":"NCT02461121","phase":"PHASE3","title":"HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk","status":"COMPLETED","sponsor":"The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","startDate":"2004-05","conditions":"Acute Myeloid Leukemia","enrollment":156},{"nctId":"NCT02386332","phase":"","title":"A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies","status":"UNKNOWN","sponsor":"Instituto de Investigacion Sanitaria La Fe","startDate":"2015-03","conditions":"Hematologic Malignancies","enrollment":206},{"nctId":"NCT00589563","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-05","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection","enrollment":32},{"nctId":"NCT00608517","phase":"NA","title":"Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil","status":"TERMINATED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2005-09","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CYCLOPHOSPHAMIDE,FLUDARA,ANTI-THYMOCYTE GLOBULINE"],"phase":"phase_3","status":"active","brandName":"Cyclophosphamide-fludarabine-anti thymocyte globulin","genericName":"Cyclophosphamide-fludarabine-anti thymocyte globulin","companyName":"Cooperative Study Group A for Hematology","companyId":"cooperative-study-group-a-for-hematology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses cyclophosphamide and fludarabine to deplete immune cells, followed by anti-thymocyte globulin to further suppress T-cell mediated rejection, typically used as conditioning for hematopoietic stem cell transplantation. Used for Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies, Conditioning regimen for allogeneic hematopoietic stem cell transplantation in severe aplastic anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}